Monashee Investment Management LLC Makes New Investment in Kymera Therapeutics, Inc. $KYMR

Monashee Investment Management LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 4th quarter, Holdings Channel.com reports. The fund bought 100,000 shares of the company’s stock, valued at approximately $7,781,000. Kymera Therapeutics comprises approximately 4.4% of Monashee Investment Management LLC’s investment portfolio, making the stock its 7th biggest holding.

Several other large investors also recently added to or reduced their stakes in the business. US Bancorp DE grew its position in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after acquiring an additional 166 shares in the last quarter. Larson Financial Group LLC grew its position in Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares in the last quarter. Xponance LLC grew its position in Kymera Therapeutics by 13.1% in the fourth quarter. Xponance LLC now owns 4,505 shares of the company’s stock worth $351,000 after acquiring an additional 522 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in Kymera Therapeutics by 2.2% in the fourth quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock worth $2,379,000 after acquiring an additional 645 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Kymera Therapeutics by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,496 shares of the company’s stock worth $272,000 after acquiring an additional 732 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $119.00 price objective on shares of Kymera Therapeutics in a report on Thursday, April 30th. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Finally, Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $117.14.

Insider Activity

In related news, insider Noah Goodman sold 8,264 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $87.50, for a total transaction of $723,100.00. Following the completion of the transaction, the insider directly owned 53,542 shares in the company, valued at $4,684,925. This represents a 13.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jeremy G. Chadwick sold 91,250 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $77.41, for a total transaction of $7,063,662.50. Following the transaction, the chief operating officer owned 61,202 shares of the company’s stock, valued at approximately $4,737,646.82. The trade was a 59.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 234,357 shares of company stock worth $19,072,496. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Trading Up 6.0%

NASDAQ KYMR opened at $82.96 on Friday. The company has a fifty day simple moving average of $82.83 and a 200 day simple moving average of $80.17. The company has a market cap of $6.82 billion, a P/E ratio of -23.24 and a beta of 2.02. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.82) EPS. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.